(IBRX) ImmunityBio, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IBRX) ImmunityBio, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This ImmunityBio, Inc. BCG Matrix is a company-specific strategic analysis that helps you see how its products or business units may fall into Stars, Cash Cows, Question Marks, or Dogs. The content on this page is a real preview of the actual deliverable, so you can review the format and substance before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
ANKTIVA, 1 approved product
ANKTIVA is ImmunityBio, Inc.'s only approved product, and the FDA cleared it in 2024 for BCG-unresponsive NMIBC CIS with or without papillary tumors. It is the company’s first commercial launch and the clearest Stars asset in the BCG matrix, with the strongest near-term growth runway through 2025. In a niche where BCG fails in many patients, ANKTIVA has a direct shot at becoming the core revenue driver.
BCG-unresponsive NMIBC CIS
BCG-unresponsive NMIBC CIS is a high-need bladder cancer niche with only a few approved options, including pembrolizumab and nadofaragene firadenovec. ImmunityBio, Inc.’s IL-15-based ANKTIVA + BCG was FDA-approved in April 2024 for this setting, backed by a 71% complete response rate and 56% of responders lasting at least 12 months.
That mix of clear unmet need and differentiated data makes it a strong Star candidate.
Papillary NMIBC expansion
Papillary NMIBC can meaningfully expand ImmunityBio, Inc.'s bladder franchise beyond CIS, a segment that makes up most of the roughly 75% of bladder cancers diagnosed as non-muscle-invasive disease. That widens the treatable pool and can lift adoption if clinical and regulatory support keeps building. In a market where bladder cancer drives over 80,000 U.S. cases a year, a broader label would strengthen the Star profile.
Bladder cancer commercial launch
ImmunityBio’s bladder cancer launch, led by Anktiva for BCG-unresponsive NMIBC with CIS, moves the story from R&D to revenue. The U.S. sees about 83,000 new bladder cancer cases a year, so even early uptake can compound if reimbursement, physician adoption, and supply scale. This is still a growth-heavy launch, not a mature cash engine.
- Commercial stage now
- Reimbursement drives uptake
- Adoption can compound sales
NK and T cell activation platform
ANKTIVA anchors ImmunityBio’s NK and T cell activation platform, which is a classic Star trait because one immune backbone can support several oncology combinations. In 2024, ANKTIVA was the first FDA-approved IL-15 agonist, and ImmunityBio reported product revenue of about $50 million, showing early commercial traction for a platform built to scale across tumors.
- Single biology, multiple combo paths
- NK and T cell activation is the core
- First FDA-approved IL-15 agonist
- Platform leverage supports Star status
ANKTIVA: ImmunityBio’s First Big Growth Engine
ANKTIVA is ImmunityBio, Inc.'s clear Star: it is the only approved product, launched in 2024 for BCG-unresponsive NMIBC CIS, and reported about 71% complete response with 56% of responders lasting at least 12 months. That gives it the best near-term growth path in a niche with few options and about 83,000 U.S. bladder cancer cases a year.
| Star driver | Key data |
|---|---|
| ANKTIVA approval | April 2024 |
| CR rate | 71% |
| 12-month durability | 56% |
| 2024 product revenue | About $50 million |
What is included in the product
Detailed Word Document
BCG Matrix view of ImmunityBio’s portfolio, showing where to invest, hold, or exit across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
Quick BCG Matrix view of ImmunityBio, Inc. to spotlight pain points and prioritize portfolio moves.
Reference Sources
Provides a credible source trail for ImmunityBio, Inc., helping users verify key assumptions quickly and make better-informed decisions.
Cash Cows
No true mature cash cow
By end-2025, ImmunityBio, Inc. still had just 1 commercial product, ANKTIVA, and no broad mature portfolio to harvest steady cash from. Most of its other assets remained trial-stage or growth-stage, so they were still consuming capital rather than funding the business. That leaves the BCG matrix with limited true Cash Cow inventory and very little mature, repeatable cash flow.
ANKTIVA recurring U.S. sales
ANKTIVA’s U.S. sales are recurring, not one-off, because the therapy is used in repeat treatment cycles for a chronic oncology niche. In ImmunityBio, Inc.’s mix, that makes it the closest thing to a Cash Cow: if demand stays steady, each added sale should need less new R&D spend and can lift operating cash flow. That matters because the U.S. launch is still early, so even modest, stable prescription growth can improve margins faster than a new product buildout.
Government collaboration receipts
ImmunityBio, Inc. lists government collaborations with the National Cancer Institute and the National Institute on Deafness and Communication Disorders, and this kind of support can help offset R&D burn. It is steady, lower-risk cash flow, but it is not a scalable growth franchise. For a Cash Cow label, the value is funding stability, not margin expansion.
License portfolio income
ImmunityBio’s license portfolio spans 8 named partners: CytRx, EnGeneIC, GlobeImmune, IDRI, Sanford Health, Shenzhen Beike, Sorrento, and Viracta. That kind of income is usually modest, but it can repeat without the heavy cash burn of new R&D bets, so it fits BCG Cash Cows better than a pipeline story.
- 8 licensing ties
- Repeatable, low-burn income
- More stable than new pipeline risk
Manufacturing scale efficiencies
ImmunityBio, Inc. can get better unit economics as ANKTIVA volume rises, because the same plant, QC, and regulatory costs get spread over more doses and more treatment sites. That is classic Cash Cow behavior once a biologic launch matures and demand steadies.
As of 2025, ImmunityBio was still in the launch build phase, so the scale benefit is tied to dose growth, site expansion, and higher manufacturing utilization, not just price. The more recurring the orders, the more fixed cost leverage matters.
- Higher volume lowers cost per dose
- More sites spread fixed costs wider
- Mature launches can support cash flow
ImmunityBio’s Cash Cows Remain Thin: ANKTIVA Carries the Load
ImmunityBio, Inc. has very few Cash Cows. By end-2025, ANKTIVA was still its only commercial product, so recurring U.S. sales were the main stable cash source. Government collaborations and 8 licensing ties add modest, lower-burn income, but they do not yet form a true mature cash engine.
| Cash Cow source | 2025 signal |
|---|---|
| ANKTIVA | 1 commercial product |
| Licenses and grants | 8 ties; modest repeat income |
Get Your Copy
ImmunityBio, Inc. Reference Sources
The ImmunityBio, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No sample pages, no placeholder text—just the complete, professionally formatted report. Once purchased, the full file is instantly available for download and use. What you see here is what you get.
Dogs
hAd5 SARS-CoV-2 vaccine
hAd5 SARS-CoV-2 vaccine is Dog-like for ImmunityBio, Inc. in 2025: the COVID vaccine market stayed dominated by Pfizer-BioNTech and Moderna, while this program had no disclosed commercial sales. Low share and weak growth mean it did not emerge as a market leader by year-end 2025.
hAd5 HIV vaccine
hAd5 HIV vaccine sits in the Dogs quadrant: HIV vaccine work is still a long, high-fail field, and ImmunityBio has not shown commercial scale here. In 2025, the Company reported no material HIV vaccine revenue, so returns remain uncertain against ongoing R&D spend. With no market leadership and a slow path to approval, this program looks like high effort for low near-term payoff.
Legacy infectious-disease programs
ImmunityBio, Inc.’s legacy infectious-disease programs sit outside the core bladder-cancer launch, so they are a Dogs-style drag unless they can prove late-stage value. These assets still face long development cycles and unclear differentiation, while the company’s 2025 focus remained ANKTIVA and bladder cancer. Without near-term clinical or commercial traction, they can keep using cash with limited payoff.
Non-core partner-derived assets
ImmunityBio, Inc. has partner-derived legacy assets that fit a Dog profile when they do not move into late-stage development or near-term sales. In 2025, the market still treated these assets as non-core, while value creation stayed tied to ANKTIVA and other active programs.
That means cash can sit in dormant licenses instead of funding higher-return work. In biotech, idle partnered assets often stay on the books with little strategic lift unless a trial win or deal re-pricing changes the path.
- Legacy licenses add cost, not growth.
- Advancement is the key value trigger.
- Idle assets usually rank as Dogs.
Early vaccine tooling
Early vaccine tooling looks like a BCG "Dog" for ImmunityBio, Inc.: scientifically useful, but weak commercially without approved uses. In 2025, ImmunityBio still depended on Anktiva-linked sales, while platform tools alone had no clear market share or durable revenue stream. That makes this a cash-risk area unless new clinical data turns it into an approved product.
- Useful science, weak sales
- No approved indication, no scale
- High burn risk if trials slip
ImmunityBio’s Dog Assets: Cash-Draining, Revenue-Light
ImmunityBio, Inc.’s Dogs are the hAd5 SARS-CoV-2 vaccine, hAd5 HIV vaccine, and other legacy infectious-disease assets: in 2025 they had no disclosed commercial scale, no clear market share, and no near-term revenue driver. These programs stayed non-core while ANKTIVA and bladder cancer held company focus, so they still tied up cash with limited payoff. In BCG terms, they look like capital traps unless a late-stage win changes the profile.
| Dog asset | 2025 signal | BCG read |
|---|---|---|
| hAd5 SARS-CoV-2 | No disclosed sales | Dog |
| hAd5 HIV | No material revenue | Dog |
| Legacy licenses | Non-core, idle | Dog |
Question Marks
Pancreatic cancer trials
Pancreatic cancer is a big, high-unmet-need market, with about 66,440 new U.S. cases and 51,750 deaths expected in 2025, and a 5-year survival rate near 13%. ImmunityBio, Inc.'s pancreatic program is still early and small, so it fits the Question Mark quadrant today. Strong trial data could lift its value fast, but revenue is not yet meaningful.
Non-small cell lung cancer trials
NSCLC is a huge immuno-oncology target: it makes up about 85% of lung cancers, and global lung cancer cases were about 2.5 million in 2022. ImmunityBio’s NSCLC work sits in trial-stage data, so the company is still proving share, not harvesting it. That fits a Question Mark: the upside is large, but adoption is still unproven.
Muscle-invasive bladder cancer
Moving into muscle-invasive bladder cancer could open a larger market, since about 25% of bladder cancers are muscle-invasive and the global bladder cancer market is still expanding in 2025-2026. But ImmunityBio, Inc. is not a leader in this segment yet, and ANKTIVA remains tied mainly to NMIBC use. So this is still a Question Mark: high-growth upside, but future MIBC data must prove it.
Combination immunotherapy studies
ImmunityBio, Inc. uses combination immunotherapy to widen response and label breadth, and that can pay off if the data hold. The bet is still uncertain, though, because each added study keeps R&D spending high while the company has only one U.S. approved regimen for Anktiva in BCG-unresponsive NMIBC. In BCG terms, this fits a Question Mark: high upside, but heavy cash use until proof lands.
- One approved U.S. regimen today.
- Combo trials aim to expand labels.
- Value depends on clinical readouts.
Other solid tumor expansions
ImmunityBio, Inc. is pushing its platform into other solid tumors beyond bladder, but share is still tiny. That makes these programs classic Question Marks: the markets are huge, with global lung cancer near 2.5 million new cases, colorectal near 1.9 million, and breast near 2.3 million, yet commercial traction is still early.
- Big TAM, low share.
- High upside, high execution risk.
- Proof of adoption is still limited.
ImmunityBio’s Big Bets: High Upside, Still Too Early to Call a Star
ImmunityBio, Inc.’s Question Marks are early-stage but tied to large markets: pancreatic cancer, NSCLC, and bladder cancer. ANKTIVA has one U.S. approved use in BCG-unresponsive NMIBC, while broader combo trials are still unproven. The upside is real, but 2025-2026 revenue share is still too small to call any of these Stars.
| Program | 2025-2026 status | Signal |
|---|---|---|
| Pancreatic | 66,440 U.S. cases | High upside, low traction |
| NSCLC | 2.5M global cases | Big TAM, trial-stage only |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.